Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

'Beautiful Blood': How CSL Became a Global Success Story

Saturday, June 2, 2018   (0 Comments)
Share |



Peter Schiff spent much of his life donating blood to the Australian Red Cross. He started giving blood in 1953 as a medical student in Sydney and continued until recently.

So it’s fitting that the 83-year-old’s investments in the blood business – he was one of CSL’s early investors when the company listed on the Australian Securities Exchange in 1994 – have made him a small fortune.

CSL listed with a market value of $299 million, at $2.30 a share (equivalent to 81¢ today). Today, CSL shares are trading at $185 and analysts are betting the price will soon reach $200 or  more.

The once-small cap biotech now sits alongside the big banks and miners as its market capitalisation edges above $83 billion.

CSL competes on the world stage to deliver life-saving drugs and is managing this high-risk game alongside the world's best in the business – names like Sanofi, Shire, Grifols and Octapharma.


Read more.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal